Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Drop in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large decline in short interest in June. As of June 15th, there was short interest totaling 23,029 shares, a decline of 37.5% from the May 31st total of 36,835 shares. Based on an average daily trading volume, of 76,196 shares, the short-interest ratio is currently 0.3 days. Currently, 0.4% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research firms have recently weighed in on NEUP. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Neuphoria Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $21.00.

Institutional Investors Weigh In On Neuphoria Therapeutics

Hedge funds have recently modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of Neuphoria Therapeutics by 33.3% in the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after buying an additional 4,325 shares during the period. Persistent Asset Partners Ltd increased its stake in Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after acquiring an additional 8,495 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in Neuphoria Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd purchased a new stake in Neuphoria Therapeutics in the fourth quarter valued at $47,000. Finally, Boothbay Fund Management LLC purchased a new stake in Neuphoria Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Price Performance

Neuphoria Therapeutics stock traded down $0.13 during trading on Thursday, reaching $3.42. 97,557 shares of the company were exchanged, compared to its average volume of 57,270. Neuphoria Therapeutics has a 52-week low of $3.19 and a 52-week high of $21.40. The company has a market capitalization of $18.47 million, a P/E ratio of -0.31 and a beta of 0.74. The stock’s 50 day simple moving average is $4.84 and its two-hundred day simple moving average is $4.44.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.47. As a group, equities analysts forecast that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.